Individualized Homeopathic Medicines in Treatment of Hyperuricemia: Evaluation by Double-Blind, Randomized, Placebo-Controlled Trial.

IF 1.2 4区医学 Q3 INTEGRATIVE & COMPLEMENTARY MEDICINE Homeopathy Pub Date : 2023-05-01 DOI:10.1055/s-0042-1751272

Priyanka Ghosh, Subhasish Ganguly, Shyamal Kumar Mukherjee, Souvik Dutta, Abdur Rahaman Shaikh, Sk Swaif Ali, Navin Kumar Singh, Pulakendu Bhattacharya, Munmun Koley, Subhranil Saha

{"title":"Individualized Homeopathic Medicines in Treatment of Hyperuricemia: Evaluation by Double-Blind, Randomized, Placebo-Controlled Trial.","authors":"Priyanka Ghosh, Subhasish Ganguly, Shyamal Kumar Mukherjee, Souvik Dutta, Abdur Rahaman Shaikh, Sk Swaif Ali, Navin Kumar Singh, Pulakendu Bhattacharya, Munmun Koley, Subhranil Saha","doi":"10.1055/s-0042-1751272","DOIUrl":null,"url":null,"abstract":"Introduction: Hyperuricemia (HU) is a major health issue in India and across the globe. It increases the disease burden and hampers quality of life. This study was aimed at exploring the effects of individualized homeopathic medicines (IHMs) against placebo in the treatment of HU.Methods: This double-blind, randomized, placebo-controlled trial was conducted on 60 patients suffering from HU in the outpatient department of D. N. De Homoeopathic Medical College and Hospital, Kolkata. Each patient received either IHMs or identical-looking placebos, along with advice on dietary modifications irrespective of codes. Serum uric acid (SUA) level was the primary outcome measure; the HU quality of life questionnaire (HUQLQ) and the Measure Yourself Medical Outcome Profile version 2 (MYMOP-2) were the secondary outcomes; all measured at baseline, and every month, up to 3 months. Group differences were examined by two-way (split-half) repeated-measures analysis of variance after adjusting for baseline differences. Significance level was set at p ≤0.05, two-tailed.Results: The intention-to-treat sample (n = 58) was analyzed. Between-group differences in SUA levels (F 1, 56 = 13.833, p <0.001), HUQLQ scores (F 1, 56 = 32.982, p <0.001) and MYMOP-2 profile scores (F 1, 56 = 23.873, p <0.001) were statistically significant, favoring IHMs against placebos, with medium to large effect sizes. Calcarea carbonica and Pulsatilla nigricans were the most frequently prescribed medicines. No serious adverse events were reported from either of the groups.Conclusion: IHMs showed significantly better results than placebos in reducing SUA levels and improving quality of life in patients suffering from HU.Trial registration: CTRI/2019/10/021503; UTN: U1111-1241-1431.","PeriodicalId":13227,"journal":{"name":"Homeopathy","volume":"112 2","pages":"85-96"},"PeriodicalIF":1.2000,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Homeopathy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1055/s-0042-1751272","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INTEGRATIVE & COMPLEMENTARY MEDICINE","Score":null,"Total":0}

引用次数: 2

Abstract

Introduction: Hyperuricemia (HU) is a major health issue in India and across the globe. It increases the disease burden and hampers quality of life. This study was aimed at exploring the effects of individualized homeopathic medicines (IHMs) against placebo in the treatment of HU.

Methods: This double-blind, randomized, placebo-controlled trial was conducted on 60 patients suffering from HU in the outpatient department of D. N. De Homoeopathic Medical College and Hospital, Kolkata. Each patient received either IHMs or identical-looking placebos, along with advice on dietary modifications irrespective of codes. Serum uric acid (SUA) level was the primary outcome measure; the HU quality of life questionnaire (HUQLQ) and the Measure Yourself Medical Outcome Profile version 2 (MYMOP-2) were the secondary outcomes; all measured at baseline, and every month, up to 3 months. Group differences were examined by two-way (split-half) repeated-measures analysis of variance after adjusting for baseline differences. Significance level was set at p ≤0.05, two-tailed.

Results: The intention-to-treat sample (n = 58) was analyzed. Between-group differences in SUA levels (F _{1, 56} = 13.833, p <0.001), HUQLQ scores (F _{1, 56} = 32.982, p <0.001) and MYMOP-2 profile scores (F _{1, 56} = 23.873, p <0.001) were statistically significant, favoring IHMs against placebos, with medium to large effect sizes. Calcarea carbonica and Pulsatilla nigricans were the most frequently prescribed medicines. No serious adverse events were reported from either of the groups.

Conclusion: IHMs showed significantly better results than placebos in reducing SUA levels and improving quality of life in patients suffering from HU.

Trial registration: CTRI/2019/10/021503; UTN: U1111-1241-1431.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

个体化顺势疗法药物治疗高尿酸血症:双盲、随机、安慰剂对照试验评价

导读:高尿酸血症(HU)是印度和全球的一个主要健康问题。它增加了疾病负担，影响了生活质量。本研究旨在探讨个体化顺势疗法药物(IHMs)与安慰剂在治疗胡氏综合征中的作用。方法:采用双盲、随机、安慰剂对照的方法，对加尔各答顺势疗法医学院门诊部60例HU患者进行研究。每位患者要么接受ihm，要么接受外观相同的安慰剂，并在饮食调整方面提供建议，而不考虑编码。血清尿酸(SUA)水平是主要结局指标;HU生活质量问卷(HUQLQ)和自我测量医疗结局概况第2版(mymop2)是次要结局;所有这些都是在基线上测量的，每个月，直到3个月。在调整基线差异后，采用双向重复测量方差分析检查组间差异。显著性水平设为p≤0.05，双侧。结果:对意向治疗样本(n = 58)进行了分析。SUA水平组间差异(f1, 56 = 13.833, f1, 56 = 32.982, f1, 56 = 23.873)，处方频次最高的药物为石炭石和白头翁。两组均未报告严重不良事件。结论:IHMs在降低SUA水平和改善HU患者生活质量方面的效果明显优于安慰剂。试验报名:CTRI/2019/10/021503;UTN: u1111 - 1241 - 1431。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Homeopathy 医学-全科医学与补充医学

CiteScore

3.40

自引率

70.60%

发文量

审稿时长

20.1 weeks

期刊介绍： Homeopathy is an international peer-reviewed journal aimed at improving the fundamental understanding and clinical practice of homeopathy by publishing relevant high-quality original research articles, reviews, and case reports. It also promotes commentary and debate on matters of topical interest in homeopathy.